Newmont Accrued Royalties (Current) increased by 17.1% to $212.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.1%, from $178.00M to $212.00M. Over 2 years (FY 2020 to FY 2025), Accrued Royalties (Current) shows an upward trend with a 60.8% CAGR.
An increase generally correlates with higher sales of licensed products, reflecting successful commercialization efforts.
The liability representing royalty payments that have been earned by third parties based on product sales but have not y...
Specific to companies with licensed technology or intellectual property, common in the biotech sector.
accrued_royalties_current| Q2 '21 | Q3 '21 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $70.00M | $89.00M | $165.00M | $178.00M | $179.00M | $188.00M | $181.00M | $212.00M |
| QoQ Change | — | +27.1% | +85.4% | +7.9% | +0.6% | +5.0% | -3.7% | +17.1% |
| YoY Change | — | — | — | — | — | — | +9.7% | +19.1% |